Basic Information
| RNALocate ID: | RLID:11000696 |
| RNA Symbol: | hsa-miR-17-5p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-17 |
| RNA ID: | miRBase:MIMAT0000070 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23539611 |
| Tissue/Cell Line: | Seminal plasma |
| Method: | Microarray |
| Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001267 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01001268 | Cytoplasm | Neural progenitor cells | 21363885 |
| RLID:01001269 | Cytoplasm | Cell line (HeLa) | 21695135 |
| RLID:01001270 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001271 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001272 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001273 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001274 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001275 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01001276 | Nucleus | Colon adenocarcinoma cells | 20864815 |
| RLID:11000686 | Exosome | Serum | 29143228 |
| RLID:11000687 | Exosome | Peripheral blood mononuclear cells | 19002258 |
| RLID:11000688 | Exosome | Saliva | 19627513 |
| RLID:11000689 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11000690 | Exosome | Breast milk | 22211110 |
| RLID:11000691 | Exosome | Brain tissue | 23382797 |
| RLID:11000692 | Exosome | Plasma | 23663360 |
| RLID:11000693 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11000694 | Exosome | Cerebrospinal fluid | 25420022 |
| RLID:11000695 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11000697 | Microvesicle | Follicular fluid | 23666971 |
| RLID-D:11000009 | Exosome | B lymphoblastoid cells|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Lymphoma tissue|Mast cells|Tongue tissue | |
| RLID-D:11000269 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-17-5p | Diffuse large b cell lymphoma | MNDR-E-MI-19078 |
| MNDR | hsa-miR-17-5p | Splenic marginal zone lymphoma | MNDR-E-MI-19079 |
| MNDR | hsa-miR-17-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-19080 |
| MNDR | hsa-miR-17-5p | Oral squamous cell carcinoma | MNDR-E-MI-19081 |
| MNDR | hsa-miR-17-5p | Large cell neuroendocrine cancer | MNDR-E-MI-19082 |
| MNDR | hsa-miR-17-5p | Follicular cleaved lymphoma | MNDR-E-MI-19083 |
| MNDR | hsa-miR-17-5p | Medulloblastoma | MNDR-E-MI-19084 |
| MNDR | hsa-miR-17-5p | B cell lymphoma of malt type | MNDR-E-MI-19085 |
| MNDR | hsa-miR-17-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-19086 |
| MNDR | hsa-miR-17-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-19087 |
| MNDR | hsa-miR-17-5p | Ovarian clear cell carcinoma | MNDR-E-MI-19088 |
| MNDR | hsa-miR-17-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-19089 |
| MNDR | hsa-miR-17-5p | Autism spectrum disorder | MNDR-E-MI-19090 |
| MNDR | hsa-miR-17-5p | Lymphoma | MNDR-E-MI-19091 |
| MNDR | hsa-miR-17-5p | Lymphoma non-hodgkin | MNDR-E-MI-19092 |
| MNDR | hsa-miR-17-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-19093 |
| MNDR | hsa-miR-17-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-19094 |
| MNDR | hsa-miR-17-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-19095 |
| MNDR | hsa-miR-17-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-19096 |
| MNDR | hsa-miR-17-5p | Her2-receptor positive breast cancer | MNDR-E-MI-19097 |
| MNDR | hsa-miR-17-5p | Breast cancer luminal | MNDR-E-MI-19098 |
| MNDR | hsa-miR-17-5p | Lymphoblastic lymphoma | MNDR-E-MI-19099 |
| MNDR | hsa-miR-17-5p | Polycystic kidney diseases | MNDR-E-MI-19100 |
| MNDR | hsa-miR-17-5p | Thyroid carcinoma anaplastic | MNDR-E-MI-19101 |
| MNDR | hsa-miR-17-5p | Small intestine cancer | MNDR-E-MI-19102 |
| MNDR | hsa-miR-17-5p | Dermatomyositis | MNDR-E-MI-19103 |
| MNDR | hsa-miR-17-5p | Prostate cancer | MNDR-E-MI-19104 |
| MNDR | hsa-miR-17-5p | Gastric cancer | MNDR-E-MI-19105 |
| MNDR | hsa-miR-17-5p | Gastric lymphoma | MNDR-E-MI-19106 |
| MNDR | hsa-miR-17-5p | Alzheimer disease | MNDR-E-MI-19107 |
| MNDR | hsa-miR-17-5p | Intracranial aneurysm | MNDR-E-MI-19108 |
| MNDR | hsa-miR-17-5p | Bladder cancer | MNDR-E-MI-19109 |
| MNDR | hsa-miR-17-5p | Esophageal carcinoma | MNDR-E-MI-19110 |
| MNDR | hsa-miR-17-5p | Sarcoma | MNDR-E-MI-19111 |
| MNDR | hsa-miR-17-5p | Dysautonomia familial | MNDR-E-MI-19112 |
| MNDR | hsa-miR-17-5p | Primary biliary cirrhosis | MNDR-E-MI-19113 |
| MNDR | hsa-miR-17-5p | Leukemia | MNDR-E-MI-19114 |
| MNDR | hsa-miR-17-5p | Huntington disease | MNDR-E-MI-19115 |
| MNDR | hsa-miR-17-5p | Chorea | MNDR-E-MI-19116 |
| MNDR | hsa-miR-17-5p | Cardiovascular disease | MNDR-E-MI-19117 |
| MNDR | hsa-miR-17-5p | Carotid stenosis | MNDR-E-MI-19118 |
| MNDR | hsa-miR-17-5p | Lung cancer | MNDR-E-MI-19119 |
| MNDR | hsa-miR-17-5p | Down syndrome | MNDR-E-MI-19120 |
| MNDR | hsa-miR-17-5p | Parkinson disease | MNDR-E-MI-19121 |
| MNDR | hsa-miR-17-5p | Basal-like breast cancer | MNDR-E-MI-19122 |
| MNDR | hsa-miR-17-5p | Thyroid cancer | MNDR-E-MI-19123 |
| MNDR | hsa-miR-17-5p | Pituitary neoplasms | MNDR-E-MI-19124 |
| MNDR | hsa-miR-17-5p | Pancreatic cancer | MNDR-E-MI-19125 |
| MNDR | hsa-miR-17-5p | Malignant melanoma | MNDR-E-MI-19126 |
| MNDR | hsa-miR-17-5p | Lesch-nyhan syndrome | MNDR-E-MI-19127 |
| MNDR | hsa-miR-17-5p | Rectum adenocarcinoma | MNDR-E-MI-19128 |
| MNDR | hsa-miR-17-5p | Nephroblastoma | MNDR-E-MI-19129 |
| MNDR | hsa-miR-17-5p | Colon cancer | MNDR-E-MI-19130 |
| MNDR | hsa-miR-17-5p | Ischemic attack transient | MNDR-E-MI-19131 |
| MNDR | hsa-miR-17-5p | Colon adenocarcinoma | MNDR-E-MI-19132 |
| MNDR | hsa-miR-17-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-19133 |
| MNDR | hsa-miR-17-5p | Familial ovarian cancer | MNDR-E-MI-19134 |
| MNDR | hsa-miR-17-5p | Acromegaly | MNDR-E-MI-19135 |
| MNDR | hsa-miR-17-5p | Prostate adenocarcinoma | MNDR-E-MI-19136 |
| MNDR | hsa-miR-17-5p | Kidney cancer | MNDR-E-MI-19137 |
| MNDR | hsa-miR-17-5p | Carcinoma ductal breast | MNDR-E-MI-19138 |
| MNDR | hsa-miR-17-5p | Invasive ductal carcinoma | MNDR-E-MI-19139 |
| MNDR | hsa-miR-17-5p | Glioblastoma | MNDR-E-MI-19140 |
| MNDR | hsa-miR-17-5p | Glioma | MNDR-E-MI-19141 |
| MNDR | hsa-miR-17-5p | Oligodendroglioma | MNDR-E-MI-19142 |
| MNDR | hsa-miR-17-5p | Central nervous system lymphoma | MNDR-E-MI-19143 |
| MNDR | hsa-miR-17-5p | Chordoma | MNDR-E-MI-19144 |
| MNDR | hsa-miR-17-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-19145 |
| MNDR | hsa-miR-17-5p | Epilepsy temporal lobe | MNDR-E-MI-19146 |
| MNDR | hsa-miR-17-5p | Osteosarcoma | MNDR-E-MI-19147 |
| MNDR | hsa-miR-17-5p | Liposarcoma | MNDR-E-MI-19148 |
| MNDR | hsa-miR-17-5p | Coronary artery disease | MNDR-E-MI-19149 |
| MNDR | hsa-miR-17-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-19150 |
| MNDR | hsa-miR-17-5p | Middle cerebral artery infarction | MNDR-E-MI-19151 |
| MNDR | hsa-miR-17-5p | Meningioma | MNDR-E-MI-19152 |
| MNDR | hsa-miR-17-5p | Liver cancer | MNDR-E-MI-19153 |
| MNDR | hsa-miR-17-5p | Gastric adenocarcinoma | MNDR-E-MI-19154 |
| MNDR | hsa-miR-17-5p | Cervical squamous cell carcinoma | MNDR-E-MI-19155 |
| MNDR | hsa-miR-17-5p | Pituitary adenoma | MNDR-E-MI-19156 |
| MNDR | hsa-miR-17-5p | Lung squamous cell carcinoma | MNDR-E-MI-19157 |
| MNDR | hsa-miR-17-5p | Carcinoma lung non-small-cell | MNDR-E-MI-19158 |
| MNDR | hsa-miR-17-5p | Lung adenocarcinoma | MNDR-E-MI-19159 |
| MNDR | hsa-miR-17-5p | Adrenocortical carcinoma | MNDR-E-MI-19160 |
| MNDR | hsa-miR-17-5p | Thyroid carcinoma | MNDR-E-MI-19161 |
| MNDR | hsa-miR-17-5p | Ovarian carcinoma | MNDR-E-MI-19162 |
| MNDR | hsa-miR-17-5p | Bladder urothelial carcinoma | MNDR-E-MI-19163 |
| MNDR | hsa-miR-17-5p | Pancreatic adenocarcinoma | MNDR-E-MI-19164 |
| MNDR | hsa-miR-17-5p | Cervical cancer | MNDR-E-MI-19165 |
| MNDR | hsa-miR-17-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-19166 |
| MNDR | hsa-miR-17-5p | Kidney renal clear cell carcinoma | MNDR-E-MI-19167 |
| MNDR | hsa-miR-17-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-19168 |
| MNDR | hsa-miR-17-5p | Clear cell renal cell carcinoma | MNDR-E-MI-19169 |
| MNDR | hsa-miR-17-5p | Biliary tract cancer | MNDR-E-MI-19170 |
| MNDR | hsa-miR-17-5p | Pituitary carcinoma | MNDR-E-MI-19171 |
| MNDR | hsa-miR-17-5p | Cholangiocarcinoma | MNDR-E-MI-19172 |
| MNDR | hsa-miR-17-5p | Esophageal cancer | MNDR-E-MI-19173 |
| MNDR | hsa-miR-17-5p | Liver cirrhosis | MNDR-E-MI-19174 |
| MNDR | hsa-miR-17-5p | Prolactinoma | MNDR-E-MI-19175 |
| MNDR | hsa-miR-17-5p | Lung small cell carcinoma | MNDR-E-MI-19176 |
| MNDR | hsa-miR-17-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-19177 |
| MNDR | hsa-miR-17-5p | Kidney diseases | MNDR-E-MI-19178 |
| MNDR | hsa-miR-17-5p | T acute lymphoblastic leukemia | MNDR-E-MI-19179 |
| MNDR | hsa-miR-17-5p | Acute t cell leukemia | MNDR-E-MI-19180 |
| MNDR | hsa-miR-17-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-19181 |
| MNDR | hsa-miR-17-5p | Fibromyalgia | MNDR-E-MI-19182 |
| MNDR | hsa-miR-17-5p | Pulmonary hypertension | MNDR-E-MI-19183 |
| MNDR | hsa-miR-17-5p | Adenoma | MNDR-E-MI-19184 |
| MNDR | hsa-miR-17-5p | Breast invasive carcinoma | MNDR-E-MI-19185 |
| MNDR | hsa-miR-17-5p | Hepatocellular carcinoma | MNDR-E-MI-19186 |
| MNDR | hsa-miR-17-5p | Familiar ovarian carcinoma | MNDR-E-MI-19187 |
| MNDR | hsa-miR-17-5p | B-cell lymphoma | MNDR-E-MI-19188 |
| MNDR | hsa-miR-17-5p | Rheumatoid arthritis | MNDR-E-MI-19189 |
| MNDR | hsa-miR-17-5p | T-cell leukemia | MNDR-E-MI-19190 |
| MNDR | hsa-miR-17-5p | Retinoblastoma | MNDR-E-MI-19191 |
| MNDR | hsa-miR-17-5p | Neuroblastoma | MNDR-E-MI-19192 |
| MNDR | hsa-miR-17-5p | Chronic fatigue syndrome | MNDR-E-MI-19193 |
| MNDR | hsa-miR-17-5p | Chronic myeloid leukemia | MNDR-E-MI-19194 |
| MNDR | hsa-miR-17-5p | Hodgkin lymphoma | MNDR-E-MI-19195 |
| MNDR | hsa-miR-17-5p | Burkitt lymphoma | MNDR-E-MI-19196 |
| MNDR | hsa-miR-17-5p | Lymphosarcoma | MNDR-E-MI-19197 |
| MNDR | hsa-miR-17-5p | Tonsil cancer | MNDR-E-MI-19198 |
| MNDR | hsa-miR-17-5p | Psoriasis | MNDR-E-MI-19199 |
| MNDR | hsa-miR-17-5p | Acute myelocytic leukemia | MNDR-E-MI-19200 |
| MNDR | hsa-miR-17-5p | Colorectal cancer | MNDR-E-MI-19201 |
| MNDR | hsa-miR-17-5p | Nasopharyngeal carcinoma | MNDR-E-MI-19202 |
| MNDR | hsa-miR-17-5p | Type 2 diabetes mellitus | MNDR-E-MI-19203 |
| MNDR | hsa-miR-17-5p | Multiple myeloma | MNDR-E-MI-19204 |
| MNDR | hsa-miR-17-5p | Uterine cervical neoplasms | MNDR-E-MI-19205 |
| MNDR | hsa-miR-17-5p | Ependymoma | MNDR-E-MI-19206 |
| MNDR | hsa-miR-17-5p | Nasopharyngeal cancer | MNDR-E-MI-19207 |
| MNDR | hsa-miR-17-5p | Prostatic neoplasms | MNDR-E-MI-19208 |
| MNDR | hsa-miR-17-5p | Arsenic poisoning | MNDR-E-MI-19209 |
| MNDR | hsa-miR-17-5p | Stroke lacunar | MNDR-E-MI-19210 |
| MNDR | hsa-miR-17-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-19211 |
| MNDR | hsa-miR-17-5p | Breast cancer her3+ negative | MNDR-E-MI-19212 |
| MNDR | hsa-miR-17-5p | Duke A | MNDR-E-MI-19213 |
| MNDR | hsa-miR-17-5p | Tubulovillous adenoma | MNDR-E-MI-19214 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABCA1 | Homo sapiens | RR00022096 |
TOP